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ABSTRACT: Dextrin, a glucose polymer with low molecular weight, was used to develop a fully resorbable hydrogel, without
using chemical initiators. Dextrin was first oxidized (oDex) with sodium periodate and then cross-linked with adipic acid
dihidrazide, a nontoxic cross-linking molecule. Furthermore, a new bidimensional composite hydrogel, made of oxidized dextrin
incorporating dextrin nanogels (oDex-nanogel), was also developed. The oDex hydrogels showed good mechanical properties
and biocompatibility, allowing the proliferation of mouse embryo fibroblasts 3T3 cultured on top of the gel. The gelation time
may be controlled selecting the concentrations of the polymer and reticulating agent. Both the oDex and oDex-nanogel hydrogels
are biodegradable and present a 3-D network with a continuous porous structure. The obtained hybrid hydrogel enables the
release of the dextrin nanogel over an extended period of time, paralleling the mass loss curve due to the degradation of the
material. The dextrin nanogel allowed the efficient incorporation of interleukin-10 and insulin in the oDex hydrogel, providing a
sophisticated system of controlled release. The new hydrogels present promising properties as an injectable carrier of bioactive
molecules. Both proteins and poorly water-soluble low-molecular-weight drugs are efficiently encapsulated in the nanogel, which
performs as a controlled release system entrapped in the hydrogel matrix.
■ INTRODUCTION
Therapeutic proteins are becoming available for the treatment
of a wide range of diseases, among others cancer, autoimmune
diseases, and metabolic disorders. A main problem limiting the
efficiency of protein therapeutics is the reduced stability and
short circulation half-lives after parenteral administration (i.e.,
intravenous, intramuscular, or subcutaneous).1 As a result of
the invasive nature, injectable formulations are frequently faced
with patient discomfort and noncompliance. In the case of
proteins, susceptibility to proteolysis and colloidal instability are
additional difficulties. Consequently, a high drug concentration
or a high dosing frequency becomes necessary, which may lead
to adverse side effects.1 Therefore, protein delivery systems are
urgently needed for the enhancement of the biopharmaceuticals
bioavailability and selectivity, enabling a targeted controlled
release profile. Aiming at achieving an effective protein delivery,
carriers such as liposomes, polymer micelles, and hydrogels
(micro- and nano-hydrogels) have been developed.1−4
Hydrogels are used in clinical practice and experimental
medicine in diverse applications, including tissue engineering and
as drug delivery systems.5,6 They can be achieved through chemical
or physical cross-linking of polymers (natural or synthetic), their
properties depending on the chemical composition, cross-
linking density, and hydrophobicity. Hydrogels are commonly
considered as highly biocompatible, owing to the high water
content and also to the physiochemical similarity with the
native extracellular matrix. Starch-based polymers, as dextrin,
are examples of natural polymers with great potential for the
development of hydrogels owing to its proven clinical toler-
ability and efficient absorption due to degradation by
amylases.7,8 Recently, Carvalho et al.9,10 produced dextrin
hydrogels, namely, dextrin-vinyl acrylate (Dex-VA) and dextrin-
hydroxyethylmethacrylate (Dex-HEMA), and verified their
noncytotoxicity as well as their appealing diffusivity and
degradability profiles for targeted delivery therapeutics. More-
over, Gonca̧lves et al. developed and characterized a nanogel
obtained by self-assembling of hydrophobized dextrin.11,12 The
nanogel obtained has high colloidal stability and spherical
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shape. In previous work,13 it was shown that dextrin nanogels
effectively incorporated and stabilized a recombinant mutated
interleukin-10 (rIL-10), allowing for the release of biologically
active rIL-10 over time.
However, hydrogels present some limitations regarding drug
delivery: the high water content and large pore sizes frequently
result in relatively rapid release. In the past decade, composite
systems where micro- or nano-hydrogels are incorporated in a
bulk hydrogel matrix appeared as a platform for drug
delivery.14−17 The micro- or nano-hydrogel particles can act as
a drug reservoir from which release can be triggered by a suitable
stimulus or simply released in a diffusion-controlled manner.
Simultaneous diffusion of different molecules at different rates can
be obtained from the same platform by adding two (or more)
populations of micro or nanogels, each loaded with one kind of
drug, in the same hydrogel matrix.15,17 The major advantage relies
on the improvement of the kinetic release profile of the drug, as
the nanogel phase provides an additional diffusion barrier
moderating or eliminating the initial burst release typically
observed in hydrogel or nanogel drug delivery systems.
In this work, an expeditious methodology initially developed
by Bouhadir and colleagues18 was used to prepare degradable
injectable hydrogels from oxidized dextrin (oDex) without the
use of any chemical initiator. The networks were evaluated
regarding their rheological properties as well their degradation
at physiologic pH. A composite system made from dextrin
nanogel and oDex hydrogel is also described. Their degradation
and nanogel release profile were also evaluated. Simultaneously,
a recombinant interleukin-10 (rIL-10), an immunoregulatory
cytokine with strong anti-inflammatory activity,19,20 and insulin
(Ins), an hormone responsible for controlling the cellular
uptake, utilization, and storage of glucose,21,22 were used to
evaluate the potential of these hydrogels as controlled protein
release systems.
■ EXPERIMENTAL SECTION
Materials. All reagents used were of laboratory grade and
purchased from Sigma-Aldrich, unless stated otherwise. Dextrin -
Koldex 60 starch was a generous gift from Tate & Lyle. All other
chemicals and solvents used in this work were of the highest purity
commercially available.
Preparation of oDex Hydrogels. Dextrin Oxidation. In brief,
aqueous solutions of dextrin (2% w/v) were oxidized with a 2 mL
sodium m-periodate solution, with different concentrations to yield the
desired theoretical degree of oxidation (DOt), at room temperature,
with stirring, and in the dark. After 20 h, the oxidation reaction was
stopped by adding dropwise an equimolar amount of diethyleneglycol
to reduce any unreacted periodate. The resulting solution was dialyzed
for 3 days against water using a dialysis membrane with a molecular
weight cutoff of 1000 Da and then lyophilized for 10 days.
Determination of Aldehyde Groups by 1H NMR Analysis. The
degree of oxidation (DO) of oxidized dextrin (oDex) is defined as the
number of oxidized residues per 100 glucose residues and was
quantified using the tert-butylcarbazate (tBC) method as described
elsewhere.18,23−26 The 1H NMR spectra were used to determine DO,
calculated as a peak area ratio in the NMR spectra according to the
equation: DO (%) = (X/Y) × 100 where, X is the average integral
corresponding to the peak at δ 7.3 and Y is the average integral of the
anomeric protons at δ 4.8 and δ 5.4.
Preparation of oDex-ADH Hydrogels. oDex was dissolved in PBS
buffer (phosphate-buffered saline) (30% w/v) at room temperature,
and an adipic acid dihydrazide (ADH) solution (prepared separately)
was added at different concentrations (5, 15, and 30% in molar base,
taking into account the number of glucose residues in the original
dextrin). The cross-linking reaction was allowed to proceed during 2 h.
The material was considered as gelified when it stopped slipping along
a 90° inclined surface.
Preparation of oDex-Nanogel Hydrogels. Dextrin nanogel was
prepared as described in Carvalho et al.13 The nanogel formation was
confirmed by dynamic light scattering, as previously described.11−13
oDex, DO 40%, (30% w/v) was dissolved in PBS or in a suspension of
nanogel for ∼16 h at room temperature. Then, the oDex suspensions
were mixed with 5% (in molar base taking into account the number of
glucose residues in the original dextrin) ADH. The cross-linking was
allowed to proceed at room temperature for ∼2 h. Ahead, the oxidized
dextrin hydrogels are termed as oDex hydrogels, and the oxidized
dextrin hydrogels with incorporated dextrin nanogels are called oDex-
nanogel hydrogels.
Mechanical Analysis. The mechanical properties of cross-linked
oDex hydrogels were assessed using a Mechanical Tester - Shimadzu-
AG-IS 1 kN testing instrument. Each hydrogel disk (superficial area =
133 mm2) was placed between two parallel metallic circumferential
plates so that the compressive force would be uniform along the sample
and compressed at room temperature with a constant deformation rate
of 0.5 mm min−1. For each condition, samples in triplicate were analyzed;
the values given in the results section represent the mean and the
standard deviation.
Biocompatibility Assays. Mouse Embryo Fibroblasts 3T3
Culture. Mouse embryo fibroblasts 3T3 (ATCC CCL-164) were
grown in Dulbecco’s modified Eagle’s media supplemented with 10%
newborn calf serum (Invitrogen, U.K.) and 1 μg/mL penicillin/
streptavidin (cDMEM) at 37 °C in a 95% humidified air containing
5% CO2. At 80% confluency, 3T3 fibroblasts were harvested with 0.05%
(w/v) trypsin-EDTA and subcultivated in the same medium.
In Vitro Cytotoxicity Studies. The cytotoxicity of the un-cross-
linked macromonomer solutions (oDex and ADH) and hydrogel
degradation extracts was assessed in a 3T3 fibroblasts culture previously
incubated for 24 h (2.5 × 103 cells/well, in a 96-well polystyrene plate)
using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) assay, as briefly described below.
The oDex and ADH were sterilized by ethylene oxide (ETO) and
filtration, respectively, and dissolved in cDMEM. Increasing
concentrations of oDex and ADH were then added to the fibroblast
culture. The degradation extracts were obtained immersing oDex
hydrogels in cDMEM and incubating for 48 h at room temperature.
Subsequently, the degradation extracts were added to the fibroblast
culture. After 48 h of incubation, cell viability was accessed by MTT
assay.
To evaluate the direct cytotoxicity of the oDex hydrogels toward
fibroblasts, we used the live and dead assay (Invitrogen, U.K.). Mousse
embryo fibroblasts 3T3 were seeded (5 × 104 cells/well) in a six-well
polystyrene plate and incubated for 24 h. Then, the culture medium
was removed, and hydrogel discs (Ø 4 mm, 2 mm thickness) were
placed on the wells, in direct contact with cells. At regular time
intervals, 200 μL of a solution of 2 μM calcein AM and 4 μM ethidium
homodimer-1, in sterile PBS, were added to the wells, incubated for
30 to 45 min at 37 °C, 5% CO2 (as indicated by the manufacturer)
and visualized in a fluorescence microscope. Latex discs and agar gel
(U.S. Pharmacopeia) were used as controls. Morphological evaluation
of 3T3 cells was also made by regular light microscope observations.
Cryo-Scanning Electron Microscopy (Cryo-SEM) Analysis.
The topography and porosity of the hydrogels were studied by Cryo-
SEM. The oDex and oDex-nanogel hydrogels (30% w/v oDex, 10 mg/mL
nanogel) were rapidly immersed in liquid nitrogen slush at −210 °C for
2 min and vacuum transferred to an Alto 2500 (Gatan, Pleasanton, CA)
cryo-preparation chamber attached to a JEOL JSM 6301F scanning
electron microscope. Frozen samples were fractured at −185 °C, etched
during 90 s (to sublimate water partially from the fractured hydrogel
surface), and finally gold-coated for 2 min. Samples were viewed at
−130 °C, and the resulting SEM images were analyzed using ImageJ
software (National Institutes of Health, U.S.).
Degradation of oDex Hydrogels. After being prepared and
weighted (Wi), the hydrogels were immersed in PBS (diffusion
medium) and incubated at 37 °C. At regular intervals, they were
removed from the solutions, blotted with filter paper, weighed (Wt),
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and returned to the same container. The buffer solution was replaced
at each measurement, and the old one was stored for further analysis.
The percentage of mass loss was determined using the equation: mass
loss (%) = 100 − [(Wt/Wi) × 100]
Release Assays. Nanogel/FITC. To obtain dextrin nanogels
labeled with FITC (nanogel/FITC), a nanogel solution was formed by
dissolving 10 mg of dextrin-VMA-SC16 (VMA: vinyl methacrylate;
SC16: alkyl chain) in 1.3 mL of 0.1 M sodium phosphate buffer pH 7
and stirred for 30 min. Simultaneously, a fluorescein solution was
prepared by dissolving 5 mg of SAMSA (5-(2-(and-3)-S-
(acetylmercapto)succinoyl) amino) fluorescein (Invitrogen, U.K.) in
0.5 mL of 0.1 M NaOH and stirred for 15 min. Then, 7 μL of 6 M
HCl and 0.1 mL of 0.5 M NaPO4 buffer pH 7 were added and stirred
for 10 min. Finally, the nanogel solution and the fluorescein solution
were mixed and stirred for 30 min. Unbound FITC was separated
using a Sephadex G25 PD10 column (Amersham Biosciences)
equilibrated with PBS, and the labeled nanogel (nanogel/FITC) was
eluted with PBS.
The oDex-nanogel/FITC hydrogel was obtained as previously
described (preparation of oDex-nanogel hydrogel). Degradation assays
were also performed, as described above. The nanogel/FITC release
from the oDex-nanogel hydrogels was evaluated by fluorimetry. The
fluorescence intensity of the supernatant collected from the degrading
hydrogels, at regular intervals, was measured using a spectrofluorim-
eter (Fluorolog Horiba Jobin Yvon). Fluorescence spectra were
collected using an excitation wavelength of 460 nm and recording
emission between 470 and 600 at 1 nm intervals. The slit width was set
at 6.0 nm for the excitation and emission. The fluorescence intensity
was measured at the maximum of the peak obtained (520 nm).
The percentage of nanogel/FITC released from the oDex-nanogel
hydrogel was obtained according to the equation: Nanogel/FITC
release (%) = [nanogel/FITC]det/[nanogel/FITC]tot × 100, where
[nanogel/FITC]det is the fluorescence intensity detected in the PBS
supernatant collected during degradation and [nanogel/FITC]tot is the
fluorescence intensity obtained dispersing the nanogel/FITC in the
same volume as that used in the degradation assays.
Nanogel/rIL-10. The nanogel/rIL-10 complex was obtained by
dissolving the lyophilized dextrin-VMA-SC16 in a rIL-10 solution
(5 mg/mL nanogel, 25 μg/mL rIL-10), as previously described.13 The
oDex-nanogel/rIL-10 hydrogel was then prepared as already explained.
The oDex hydrogel with incorporated free rIL-10 was obtained by
dissolving oDex in a rIL-10 solution (25 μg/mL).
The rIL-10 release from the oDex hydrogels, after being immersed
in PBS with 10% FBS and incubated at 37 °C, was evaluated by
quantifying by enzyme-linked immunosorbent assay (ELISA), the free
rIL-10 in the diffusion medium. The percentage of rIL-10 released was
obtained by the following equation: rIL-10 release (%) = [rIL-10]det/
[rIL-10]tot × 100, where [rIL-10]det is the amount of rIL-10 detected
in the diffusion medium at determined time and [rIL-10]tot is the total
amount of rIL-10 entrapped in the dextrin nanogel or in the hydrogel.
Circular Dichroism (CD) Measurements of rIL-10. The secondary
structure of rIL-10 was investigated using CD. rIL-10 stability
(0.25 mg/mL in PBS) at 37 °C was accessed by obtaining CD spec-
tra of the sample at determined intervals of time. Spectra were
obtained as described in Carvalho et al.13
Nanogel/Ins-FITC. To obtain Ins labeled with FITC (Ins-FITC), we
prepared a 5 mg/mL Ins solution in 0.1 M sodium carbonate buffer
pH 9.3. Simultaneously, a 0.04 mg/mL fluorescein isothiocyanate
isomer I (where referred as FITC) solution was prepared in 0.1 M
sodium carbonate buffer pH 9.3. Then, for each milligram of Ins, 20 μg
of FITC was added, mixed, and incubated overnight at 4 °C. Unbound
FITC was separated using a Sephadex G25 PD10 column (Amersham
Biosciences) equilibrated with PBS, and the labeled Ins (Ins-FITC)
was eluted with PBS.
The nanogel/Ins-FITC complex was obtained by dissolving the
lyophilized dextrin-VMA-SC16 in an Ins-FITC solution (1 mg/mL
nanogel, 0.1 mg/mL Ins-FITC). The oDex-nanogel/Ins-FITC hydro-
gel was then prepared as described. The oDex hydrogel with
incorporated free Ins-FITC was obtained by dissolving oDex in an
Ins-FITC solution (0.1 mg/mL).
The Ins-FITC release from the oDex hydrogels, after being immersed
in PBS and incubated at 37 °C, was evaluated by fluorimetry. The
fluorescence intensity of the supernatant collected from the degrading
hydrogels, at regular intervals, was measured using a Synergy HT Multi-
Mode Microplate Reader (BioTek Instruments, Winooski, VT).
Fluorescence intensities were obtained using an excitation wavelength
of 485/20 nm and recording emission at 528/20 nm. All data were
collected with KC4 software (BioTek Instruments, Winooski, VT).
The percentage of Ins-FITC released from the oDex-nanogel
hydrogel was obtained according to equation: Ins-FITC release (%) =
[Ins-FITC]det/[Ins-FITC]tot × 100, where [Ins-FITC]det is the amount
of Ins-FITC detected in the diffusion medium at determined time and
[Ins-FITC]tot is the total amount of Ins-FITC entrapped in the dextrin
nanogel or in the hydrogel.
Data Analysis. Data are presented as means ± SD of the indicated
number (n) of assays. Statistical analysis was performed using the
variance analysis method (one-way ANOVA). Significant differences
between samples were determined through the Dunnet test.
■ RESULTS AND DISCUSSION
Characterization of oDex. The periodate oxidation of
carbohydrates is widely known and routinely used as a tool for
elucidating the structural features of polysaccharides.27,28 In
homopolysaccharides, such as dextrin, this oxidation reaction is
characterized by the specific cleavage of the C2−C3 linkage of
glucopyranoside rings, yielding two aldehyde groups per
glucose unit26,29 (Scheme 1).
The quantification of aldehyde groups, that is, oxidation
degree (DO), was performed using tBC, as previously
described by Jia et al., Bouhadir et al., and Maia et al.18,23−26
Carbazates are well-known to react with aldehydes to form
stable carbazones in a similar manner to hydrazone formation,
making it possible to determine the aldehyde content of dextrin
by 1H NMR spectroscopy analysis.
Figure 1 depicts a typical 1H NMR spectrum obtained for 25%
oxidized dextrin (oDex 25%). The peaks between δ 4.0 and δ
3.4 ppm are assigned to protons at positions 2, 3, 4, 5 and 6,
whereas the peak at δ 5.4 is attributed to the glucose anomeric
proton. The spectrum also shows a small peak at δ 5.3
corresponding to the anomeric proton corresponding to α-1,6
linkages (<5% of the total dextrin8). The three peaks between
δ 7.4 and δ 7.2 are assigned to the proton attached to the carbon
with linked tBC, and the singlet at δ 1.5 is assigned to tBC.
The degree of oxidation of oDex can be easily controlled by
the relative quantity of sodium periodate used, yielding free
aldehyde reactive groups to create covalent linkages with
reticulating molecules (e.g., ADH) as well as with cellular adhesion
binding peptides [as glycine-arginine-glycine-aspartic acid-tyrosine
(GRGDY) peptide18] or even with specific drugs for targeted
controlled delivery systems.
Preparation and Characterization of oDex Hydrogels.
The ADH hydrazide groups react with the oxidized dextrin
forming a network of hydrolyzable hydrazone bonds (Scheme 1).
Once these covalent bonds are cleaved, hydrazides and dextrin
can easily diffuse across human tissues and be eliminated via renal
clearance, owing to their low molecular weight (degree of poly-
merization of ∼1330) fairly below the renal threshold (∼40 000
Da). Also, starch polymers, as dextrin, can be hydrolyzed enzy-
matically by α-amylase, which is one of the enzymes responsible
for in vivo degradation of dextrin.8,31 The solubility pattern of
oDex was accessed. It was noticed that above 30% (w/v)
solutions were extremely viscous and practically impossible to
homogenize. So, this concentration was considered to be the
threshold of oDex solubility in phosphate buffer pH 6.0 and
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was further on applied in the synthesis of all oDex hydrogels.
Next, oDex was cross-linked with various concentrations of
ADH. Hydrogel samples were initially produced with DOs
varying from 25 to 50% and ADH concentrations between 5
and 30% (in molar ratio, taking into account the number of
glucose residues in the original dextrin).
Table 1 shows the approximate gelation periods obtained. As
expected, the cross-linking times decrease with increasing DOs
as well as with increasing amounts of reticulating agent. It was
found that DOs above 40% yield very viscous solutions that
react promptly with ADH, impairing good homogenization and
resulting in mat and brittle hydrogels. Through control of DO
and ADH concentrations, a good control over the gelation time
is thus possible, making this hydrogel suitable as an injectable
system.
According to Anseth et al.,32 the compressive modulus of
hydrogels is directly proportional to the intermolecular cross-
link density. Hence, the influence of the ADH concentration,
DO, and also the type of solvent used on the extent of
intermolecular cross-linking was evaluated by quantifying the
compressive modulus of oDex hydrogels. This approach was
previously described by Bouhadir and coworkers.18 Figure 2
presents a typical compression curve obtained for oDex
hydrogels, from which the compressive modulus was deter-
mined, using the equation: compressive modulus (kPa) =
(stress max/superficial area) × 10−3.
Scheme 1. (A) Periodate Oxidation of Dextrin, Yielding Two Aldehyde Groups at Positions C2 and C3 of a D-Glucose Unit and
(B) Polymerization Reaction of Oxidized Dextrin with ADH
Figure 1. Oxidized dextrin (DO 25%) 1H NMR spectrum.





25 +c + +
32.5 ++ (∼30 min) ++ (∼10 min) ++ (∼5 min)
40 ++ (∼2 min) +++ +++
50 +++ +++ +++
aCalculated as the molar ratio of sodium periodate per initial glucose
unit in dextrin. bCalculated in molar base, taking into account the
number of glucose residues in the original dextrin. c(+) Over 1 h of
gelation, (++) gelation in <30 min, (+++) Gelation in <1 min.
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The increasing concentration of ADH resulted in a
proportionally higher compressive modulus of cross-linked
oDex hydrogels (Figure 3A), suggesting the establishment of an
increasing number of intermolecular bonds as more hydrazide
groups become available to react. The same tendency was
reported by Maia et al.25 with dextran hydrogels and by Bouhadir
et al.18 with poly(aldehyde guluronate) hydrogels, the former
revealing inferior compressive strength even with higher concen-
trations of reticulating agent. In fact, the maximum compressive
modulus obtained with guluronate hydrogels was 560 kPa, using
150 mM ADH, whereas with ca. 130 mM (equivalent to 10% in
molar ratio) a compressive modulus of 600 kPa for oDex 35%
hydrogels was registered. Thus, dextrin hydrogels appear to have
better mechanical properties.
The degree of oxidation does not seem to play a major
influence on the intermolecular cross-links. Interestingly, oDex
DO 25% hydrogels revealed the maximum compressive force
(c.a. 533 kPa), although there was no significant difference
(p > 0.05) relatively to higher DO oDex hydrogels (Figure 3B).
With 25% oxidation there is an average two to three oxidized
glucose residues per dextrin molecule (taking into account the
average polymerization degree of dextrin, which is ca. 10−13).
Hence each molecule must participate in two distinct bonds
with different molecules to be efficiently reticulated. The excessive
modification of the original polymeric chain, making available a
greater number of reactive oxidized groups, does not necessarily
imply an enhancement on hydrogel’s mechanical properties,
maybe due to steric rearrangement impediment that avoids the
formation of a larger number of intermolecular bonds.
Injectable hydrogels should be able to proceed its polymer-
ization process in situ, meaning the interstitial fluids or blood
should not interfere with it, for instance, by influence of the
media pH. Also, the intrinsic conditions necessary for the
hydrogel’s formation must not be harmful to the surrounding
tissues. Hence, the pH influence on the density of inter-
molecular bonds was evaluated by measuring the compressive
modulus of various oDex hydrogels prepared in four different
solvents: double-distilled water (c.a pH 5.77), 0.1 M phosphate
buffer (pH 6.0), PBS (pH 7.4), and cDMEM (c.a pH 7.5). The
results shown in Figure 4 are in agreement with the tendency
previously verified by Bouhadir et al.18 In fact, it is well known
that the reactivity of hydrazide groups with aldehydes is opti-
mal at lower pH values. Under acidic conditions, the reactive
aldehyde groups formed upon periodate oxidation are prone to
react with the hydrazide groups, leading to hydrazone bonds.
Under neutral to basic conditions, however, slower kinetics are
Figure 2. Compression curve showing typical behavior for an oDex
DO 35% with 4% ADH hydrogel.
Figure 3. Compressive modulus of (A) cross-linked oDex hydrogels as a function of the ADH concentration (in molar ratio, taking into account the
number of glucose residues in the original dextrin, oDex DO 35% (30% w/v) in 0.1 M phosphate buffer, pH 6.0) and (B) cross-linked oDex
hydrogels as a function of the degree of oxidation of dextrin (oDex DO 35% and 5% ADH in 0.1 M phosphate buffer, pH 6.0). Results presented as
average ± SD (n = 3). ns: nonsignificant, p > 0.05; ** p < 0.01, compared with the highest concentration of ADH used.
Figure 4. Compressive modulus of cross-linked oDex hydrogels as a
function of the solvent in which they are prepared. All hydrogels were
prepared with oDex (30% w/v) and 5% ADH. Results presented as
average ± SD (n = 3). ns: nonsignificant, p > 0.05; * p < 0.05,
compared with 0.1 M phosphate buffer, pH 6.0.
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in effect, and a longer time is required for the completion of the
reaction, yielding a lower degree of functional cross-linking.
A possible explanation for the low compressive modulus
values (58 kPa) of hydrogels prepared in cDMEM, could be
supported by the presence of amino acids in solution, which
might be interacting with aldehyde groups in oDex, following
hydrolysis of hydrazone bonds.
Biocompatibility. As to characterize the biocompatibility of
the oDex hydrogels, the cytotoxicity was evaluated for un-cross-
linked macromonomer solutions, cross-linked hydrogels, as well
as its degradation products. Mouse embryo fibroblasts 3T3 cells
were used. Cytotoxicity, defined as the “in vitro evaluation of
toxicological risks using cell culture”, is a way to assess the in vitro
biocompatibility of materials to be used in biomedical applications.
Moreover, the information gained from these types of investigations
may be used in the design of further in vivo experiments.
Figure 5A depicts the MTT absorbance values obtained after
48 h of incubation with different concentrations of ADH. After
48 h of incubation, higher concentrations of ADH (2−4% w/v)
induce cell death. However, when the amount of ADH used to
form the oDex hydrogels (5% molar base corresponding to 1% w/v)
was incubated with 3T3 fibroblasts, no significant difference was
noted in MTT absorbance values.
The products of the hydrogels degradation can be potentially
cytotoxic; to evaluate its toxicity, we incubated the extracts
obtained during degradation with mouse embryo fibroblasts
3T3 cells, and MTT assay was used to measure cellular viability.
The results are shown in Figure 5B. Cellular death is observed
when the oDex degradation products are in direct contact with
cells, although this effect attenuates upon dilution. Cellular
death could be caused by the mechanical pressure or by the
diminished oxygenation and nutrient diffusion caused by the
products sedimentation observed with the undiluted degradation
products. A similar effect was observed for the oDex solutions tested
and has also been reported by other authors (Massia and Stark33
and Ferreira et al.34) using different materials.
Dex-HEMA hydrogels were previously developed by Carvalho
and coworkers.10 In vivo assays, performed by Moreira et al.,30
showed that after implantation Dex-HEMA hydrogels were quickly
and completely degraded and reabsorbed, even though in vitro
studies revealed cytotoxicity associated with Dex-HEMA degrada-
tion products. Therefore, the rapid reabsorption and excretion is
likely to minimize the biological impact observed in this assay.
To evaluate oDex hydrogels cytotoxicity, the live and dead
assay was performed. oDex hydrogels were placed in direct
contact with cells, and latex discs and agar gels were used as
controls. In Figure 6, fluorescence images of mouse embryo
fibroblasts 3T3 cells after 48 h of incubation are shown. As
expected, latex discs revealed high toxicity, as the cells appear
majorly red (dead cells). On the contrary, with agar discs and
oDex hydrogels the majority of cells are alive (green cells). It is
well-recognized that the surface chemistry of hydrogels can
influence cell adhesion and proliferation. It has already been
shown35,36 that cell proliferation is sensitive to both hydrogel
charge density and cross-linker concentration.
Figure 7 illustrates that the direct contact of oDex hydrogels
does not inhibit cell proliferation. Although in lower number as
Figure 5. MTT absorbance values obtained after 48 h of incubation of 3T3 cells (A) in direct contact with different concentrations of reticulating
agent (ADH) and (B) with degradation products (1:1, 1:2, and 1:4 dilutions) of oDex hydrogels (T0, initial cell abs; Control, abs after 48 h of
incubation). Results presented as average ± SD (n = 3). ns: nonsignificant, p > 0.05; *p < 0.05; ** p < 0.01, compared with the T0 control.
Figure 6. Fluorescence photographs of mouse embryo fibroblasts 3T3 cells stained with live and dead after 48 h of incubation. Live cells are stained
in green and dead cells are stained in red.
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compared with control wells, cells are adherent and retain the
typical fibroblast morphology.
The overall results point to the oDex hydrogels cytocompat-
ibility: in direct contact with 3T3 fibroblasts, the oDex hydrogels
do not induce cell death nor inhibit cell proliferation under the
conditions tested and for mousse embryo fibroblasts 3T3.
Cryo-SEM Analysis. The dextrin nanogel, reported in
previous publications,12,13,37,38 was incorporated in the hydro-
gel, and the hybrid hydrogel was further characterized. The
morphologies of the oDex hydrogels were examined by Cryo-
SEM. As expected, the covalent cross-linking produced 3-D
networks. As seen in Figure 8, the oDex hydrogels exhibit a
continuous porous structure, with a diameter of ∼1 μm. With a
larger amplification, the nanogel particles present in oDex-
nanogel hydrogel can be observed.
No obvious morphologic differences are noticeable compar-
ing the oDex and oDex-nanogel hydrogel formulations. All
hydrogels have random morphology and similar porous struc-
ture, and the incorporated nanogels did not have significant
influence in the morphology of the oDex hydrogel network.
Degradation Kinetics of oDex Hydrogels at Physio-
logic pH. Despite their many favorable properties, hydrogels
also have some limitations. The low tensile strength limits their
use in load-bearing applications and, as a consequence, the
premature dissolution or flow away of the hydrogel from the
targeted local site can occur. Concerning drug delivery, the
most important drawback of hydrogels relates to the quantity
and homogeneity of drug loading, which may be limited,
especially in the case of hydrophobic drugs; on the other hand,
the high water content and large pores frequently result in
relatively rapid drug release. To surmount these limitations, a
nanogel previously developed and characterized in our lab
was used to produce a new bidimensional hydrogel. Because
this nanogel is obtained by self-assembling of amphiphilic
molecules and has been shown to incorporate and stabilize
both proteins13 and small hydrophobic pharmaceuticals,39 the
presence of the nanophase may be useful for the formulation of
hydrogels as a controlled drug release system.
Figure 9A depicts the mass loss profile and nanogel release
profile of oDex and oDex-nanogel hydrogels with different
concentrations of nanogel (1 and 3 mg/mL) as a function of
time when incubated in PBS at 37 °C.
The oDex cross-link junctions are degraded along time,
leading to a correspondingly gradual swelling. When the cross-
links are hydrolyzed, the network swells, imbibing more water
and leading to further hydrolysis. For both kinds of hydrogel
(oDex and oDex-nanogel), there is a rapid initial mass loss,
likely due to the release of material with a lower cross-linking
density (2 to 3 days), followed by a second stage with a lower
rate of solubilization. Dextrin molecules may be reticulated through
1, 2, or 3 bonds; hence, their release rate is likely to be variable.
According to mass loss studies, the degradation speed of
oDex hydrogel is different from the one found in oDex-nanogel
hydrogels. In approximately 25 days, the oDex hydrogel
network is completely solubilized, whereas only ∼70% mass
loss was observed in oDex-nanogel hydrogels. Only a slight
difference in mass loss is observed comparing the two
formulations with different amounts of nanogel.
The slower degradation rate observed in the presence of the
nanogel may be assigned to a further reticulation of the
hydrogel network. Zhang et al.40 described a composite system
made of poly(N-isopropylacrylamide) (NIPAAm) hydrogel and
hydroxyl-functionalized glycerol poly(ε-caprolactone) (PGCL)-
based microspheres, where the incorporation of the hydro-
phobic PGCL-based microspheres into the hydrogel led to
greatly increased mechanical properties of the resulting
networks. These improved mechanical properties were assigned
to the existence of hydrophobic solid microspheres, which
acted like reinforcing nodes. Nuño-Donlucas et al.41 also
reported similar findings of polyacrylamide hydrogels with
Figure 7. Morphologic evaluation of 3T3 cells in direct contact with dextrin hydrogels, cell culture plates (control wells), agarose gel, and latex
rubber. (Dark shadows on the left side show part of hydrogel or latex disk.)
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increased mechanical properties by incorporating poly(methyl
methacrylate) nanoparticles. Additionally, Puig et al.42
presented a composite hydrogel of polyacrylamide nano-
particles in a polyacrylamide matrix with improved mechanical
properties.
Depending on the chemical structure of the polymer backbone,
hydrogel degradation can occur by either surface or bulk erosion.
Surface erosion takes place when the rate of erosion exceeds the
rate of water permeation into the bulk of the polymer. Bulk
erosion occurs when water molecules permeate into the bulk of
Figure 9. (A) Mass loss and (B) nanogel cumulative release profiles of oDex, oDex-nanogel (1 mg/mL and 3 mg/mL) hydrogels. Shown are mean ±
SD (n = 3).
Figure 8. Cryo-SEM images from cross-section of oDex hydrogel (A) before and (B) after immersion on PBS buffer for 24 h and (C,D) oDex-
nanogel hydrogel. Arrows show the dextrin nanogels (oDex DO 35%).
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the matrix at a faster rate than erosion, thus exhibiting complex
degradation/erosion kinetics. Most of the biodegradable polymers
used in drug delivery undergo bulk erosion, similar behavior being
observed in hydrogels made from biodegradable polymers.43 In
oDex hydrogels, degradation mainly occurs by bulk erosion, and it
is characterized by nonlinear degradation profile accompanied by
an increasing pore size, as seen in Figure 8A,B. The variation
in pore size during the degradation of the hydrogel network is
important because it affects the swelling of the hydrogel, the
diffusion of molecules, and the delivery of cells when the
hydrogels are used for cell encapsulation.44,45
Release Assays. The nanogel (labeled with FITC) release
from the oDex-nanogel hydrogels was evaluated by fluorimetry
(Figure 9B). The nanogel was gradually released over time,
paralleling the hydrogel degradation; the total fraction of
nanogel released reached 75 and 54% for oDex-nanogel 1 mg/mL
and oDex-nanogel 3 mg/mL, respectively, after 35 days. Although
a significant mass loss of the hydrogel is observed in the first few
days, a steady and continuous release of nanogel is observed in an
expanded time frame, up to 4 weeks.
Lynch and Dawson16,17 have also described a composite
material, composed of poly(N-isopropylacrylamide) (NIPAM)-
based microgel particles entrapped in a hydrogel matrix. They
called this composite material the “plum-pudding gel”. The
release of two compositionally different solutes from this com-
posite hydrogel composed of two different populations of microgel
particles embedded in a single bulk matrix was described, showing
the potential of the plum-pudding gel as a multifunctional platform
for controlled release. Later on, the same group studied the con-
trolled release of fluvastatin from the plum-pudding gel.14
These composite materials present themselves as an alternative
approach to “simply” incorporate drugs into polymer nano or
microgels. This strategy has some advantages comparatively to
those of drug-loaded polymeric particles: by separating the
functional role (of the polymeric particles) from the support
matrix (polymeric hydrogel), it can simultaneously release several
different drugs; additionally, elution of the polymeric particles
does not degrade the polymer hydrogel, which leads to a more
stable long-term elution profile. So, this composite oDex-nanogel
hydrogel could be useful to overcome the initial burst release
phenomenon often observed in nanogel and hydrogel drug
delivery systems because it allows for the nanogel slow and con-
trolled release. Preliminary assays were carried out to study the
oDex-nanogel hydrogel as a controlled release system for proteins.
Figure 10 shows the percentage of rIL-10 released from oDex
and oDex-nanogel hydrogels in PBS with 10% FBS. The
general goal of this experiment was compromised by the low
stability of rIL-10. rIL-10 is a rather unstable protein, as can be
seen on the inset of Figure 10, where it is observed that the
amount of solubilized (nonencapsulated) rIL-10 detectable
with the ELISA decreases significantly and quickly, probably
due to denaturation and aggregation. The stability of rIL-10 was
accessed at 37 °C by recording the CD spectra over time. rIL-
10, at time 0, presented a typical CD spectrum of a helical
protein, as expected.46−48 The analysis of the mean residual
ellipticity (θ) variation, at 222 nm, allowed the prediction of
the rIL-10 half life, and this sample showed a half life of 4.4 ±
0.7 days corroborating the high instability demonstrated by
the protein in this release assay.
Despite rIL-10 improved stability when encapsulated in the
nanogel (as it has been previously demonstrated13), its release
from the hydrogels (oDex and oDex-nanogel) is observed in
both cases only in the first 6−10 h of the experiment. Actually,
the amount detected in the supernatant decreased henceforward,
due to faster aggregation as compared with fresh cytokine being
released from the hydrogel. It can nevertheless be remarked that
the release of the protein occurs at low pace when encapsulated
in the nanogel, which thus seems to offer an additional control
on the release kinetics.
Therefore, more stable protein was selected to evaluate the
performance of the hydrogel-nanogel as a controlled protein
release system. The Ins-FITC release from oDex and oDex-
nanogel hydrogels, in PBS, was estimated by fluorimetry and is
displayed in Figure 11. The release profile observed was similar
in both situations: the protein is released in a slow and sustained
way for at least 40 days. However, because the incorporation of
the dextrin nanogel in the oDex hydrogel offered an additional
barrier for the release, the percentage of Ins-FITC detectable was
significantly lower when the oDex-nanogel was used, as expected.
It was also noticed that the protein did not rapidly diffuse out of
the oDex hydrogel. On the contrary, the amount of Ins-FITC
released over time was rather low compared with other studies
where different hydrogel and loading methods are used.49,50
Protein loading into, and release from, a hydrogel are con-
trolled by various factors including: the pore volume fraction;
the pore sizes and their interconnections; the size of the
protein; and also the interactions between the protein and
polymer chains. Specifically, the protein−polymer interactions
not only affect protein loading capacity and release kinetics but
also greatly influence the protein release mechanisms.31,51,52
Figure 10. rIL-10 release from oDex-rIL-10 and oDex-nanogel/rIL-10
hydrogels. Inset shows the percentage of the initial soluble rIL-10
remaining detectable using the ELISA under the same conditions as in
the release assays. Shown are mean ± SD values (n = 3).
Figure 11. Ins-FITC release from oDex-Ins-FITC and oDex-nanogel/
Ins-FITC hydrogels. Shown are mean ± SD values (n = 3).
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In some studies, proteins and other drugs are loaded by immers-
ing lyophilized hydrogels into drug solutions, and this generally
translates into to the rapid diffusion of the drugs throughout
the pores of the hydrogels.49,50 Here the oDex was dissolved in
the protein solution before ADH addition, and this allows the
spontaneous chemical reaction between the reactive aldehydes
present on the oDex and the amines of the protein, forming a
stable oDex-Ins conjugate before gelation. Because of this
conjugation, the Ins release from the oDex hydrogels do not
occur simply by diffusion. A lower degree of oDex-Ins conjuga-
tion can be obtained by adding Ins and ADH simultaneously.
Under these conditions, ∼77% Ins is released after 6 days. It
should be remarked that the oDex-Ins conjugates might play an
additional feature for the control of the protein release system.
Recently, a polymer−protein conjugate was described as a
bioresponsive polymer therapeutic to promote wound heal-
ing.31,52 This method was based on the conjugation of dextrin
with a recombinant human epidermal growth factor (rhEGF)
and the observation that α-amylase, by degrading dextrin,
allowed the slow release of biologically active rhEGF.
Accordingly, in an in vivo situation, the Ins release from the
oDex hydrogels will occur, not only by diffusion but also as a
result of dextrin degradation by the α-amylases present in the
blood. Therefore, this system may constitute a sophisticated
delivery system of which potential will be further evaluated in
vivo, namely, assessing the biocompatibility and protein release.
The contribution of amylases (in vitro and in vivo) for the
protein release will be accessed. Furthermore, the potential of
the incorporated nanogels for the encapsulation of poorly
water-soluble low-molecular-weight molecules will also be
analyzed.
■ CONCLUSIONS
In this study, oDex and oDex-nanogel hydrogels were developed
for the sustained delivery of therapeutical proteins. The oDex
hydrogels presented acceptable mechanical properties and
revealed an overall good biocompatibility. The oDex and oDex-
nanogel hydrogels were biodegradable, with a macroporous
structure, and allowed for the nanogel release over time.
rIL-10 and Ins-FITC were loaded in both hydrogels (oDex
and oDex-nanogel), and their release was evaluated. rIL-10
studies were compromised by the very low stability of the
protein. Ins-FITC was not completely released from oDex
hydrogel due to protein conjugation, and the presence of the
nanogel in the oDex-nanogel offered an additional resistance to
the Ins-FITC release translated by the lower amount of Ins-
FITC detected over time.
The straightforward preparation and the controllable release
properties of oDex hydrogels make them attractive for the
design of injectable protein delivery systems. The presence of a
dispersed hydrophobic phase in the hydrogel may represent an
important advantage of the newly developed material. The
longer sustained release of the protein is advantageous in these
kinds of applications because it may provide a continuous
delivery of protein and prevent problems of cyclic variations in
the protein concentration in blood with time and offer a
maximum pharmacological efficiency at a minimum drug dose,
reducing administration frequency and improving patient
compliance to the therapy.
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